Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE neoadjuvant orteronel plus leuprorelin versus surgery alone in localized prostate cancer
2012-000478-42Phase 2Terminated
- Sponsor
- Queen Mary University of London
- Start
- Feb 2013
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of orteronel and leuprolide in prostate cancer (PCa) (2 arms), sponsored by Queen Mary University of London. Primary endpoint: 3-year biochemical progression-free survival. Started Feb 2013; status: terminated.
02
Drugs
orteronelleuprolide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2012-000478-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000478-42.